Angel Y S Wong1, Esther W Chan1, Shweta Anand1, Alan J Worsley1, Ian C K Wong2,3. 1. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 2. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. i.wong@ucl.ac.uk. 3. Research Department of Practice and Policy, School of Pharmacy, University College London, 9-39 Brunswick Square, London, WC1N 1AX, UK. i.wong@ucl.ac.uk.
Abstract
INTRODUCTION: It was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular events as a result of macrolide use. METHODS: Several electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ≥18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration's tool. The body of evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines. RESULTS: Observational studies were found to have a short-term risk of cardiovascular outcomes including cardiovascular mortality, myocardial infarction, and arrhythmia associated with macrolides but no risk was found in randomized controlled trials. However, no association for long-term risk (ranging from >30 days to >3 years) was observed in observational studies or randomized controlled trials. LIMITATIONS: The included studies reported different units of denominators for absolute risk and used different outcome definitions, which might increase the heterogeneity. CONCLUSIONS: More studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.
INTRODUCTION: It was postulated that antibiotics including macrolides could be used for the secondary prevention of coronary heart disease but recent studies showed that macrolides increase the cardiovascular risk. We aimed to review the evidence of cardiovascular risk associated with macrolides regarding duration of effect and risk factors; and to explore the potential effect of statins for the prevention of cardiovascular events as a result of macrolide use. METHODS: Several electronic databases (PubMed, EMBASE, Cochrane library) were searched to identify eligible studies. Observational studies and randomized controlled trials that investigated the association between macrolides and cardiovascular events in adults aged ≥18 years were included. A meta-analysis was conducted to investigate the short- and long-term risks of cardiovascular mortality, myocardial infarction, arrhythmia, and stroke. Methodological quality was assessed by the Newcastle-Ottawa scale and the Cochrane Collaboration's tool. The body of evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines. RESULTS: Observational studies were found to have a short-term risk of cardiovascular outcomes including cardiovascular mortality, myocardial infarction, and arrhythmia associated with macrolides but no risk was found in randomized controlled trials. However, no association for long-term risk (ranging from >30 days to >3 years) was observed in observational studies or randomized controlled trials. LIMITATIONS: The included studies reported different units of denominators for absolute risk and used different outcome definitions, which might increase the heterogeneity. CONCLUSIONS: More studies are required to investigate the short-term cardiovascular outcomes associated with different types of macrolides. Future studies are warranted to evaluate the effect of statins for preventing excess acute cardiovascular events associated with clarithromycin or other macrolides.
Authors: Per Winkel; Jørgen Hilden; Jørgen Fischer Hansen; Per Hildebrandt; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Christian M Jespersen; Christian Gluud; Gorm Boje Jensen Journal: Cardiology Date: 2011-03-26 Impact factor: 1.869
Authors: Christian M Jespersen; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jørgen Hilden; Gorm B Jensen; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian Gluud Journal: BMJ Date: 2005-12-08
Authors: Juha Sinisalo; Kimmo Mattila; Ville Valtonen; Olli Anttonen; Jukka Juvonen; John Melin; Helena Vuorinen-Markkola; Markku S Nieminen Journal: Circulation Date: 2002-04-02 Impact factor: 29.690
Authors: Christian Gluud; Bodil Als-Nielsen; Morten Damgaard; Jørgen Fischer Hansen; Stig Hansen; Olav H Helø; Per Hildebrandt; Jørgen Hilden; Gorm Boje Jensen; Jens Kastrup; Hans Jørn Kolmos; Erik Kjøller; Inga Lind; Henrik Nielsen; Lars Petersen; Christian M Jespersen Journal: Cardiology Date: 2008-05-02 Impact factor: 1.869
Authors: Adam F M Stone; Michael A Mendall; Juan-Carlos Kaski; Tracey M Edger; Paul Risley; Jan Poloniecki; A John Camm; Timothy C Northfield Journal: Circulation Date: 2002-09-03 Impact factor: 29.690
Authors: Stuart Schembri; Peter A Williamson; Philip M Short; Aran Singanayagam; Ahsan Akram; Joanne Taylor; Anika Singanayagam; Adam T Hill; James D Chalmers Journal: BMJ Date: 2013-03-20
Authors: Amit M Patel; Salimah Shariff; David G Bailey; David N Juurlink; Sonja Gandhi; Muhammad Mamdani; Tara Gomes; Jamie Fleet; Y Joseph Hwang; Amit X Garg Journal: Ann Intern Med Date: 2013-06-18 Impact factor: 25.391
Authors: Eric M Mortensen; Ethan A Halm; Mary Jo Pugh; Laurel A Copeland; Mark Metersky; Michael J Fine; Christopher S Johnson; Carlos A Alvarez; Christopher R Frei; Chester Good; Marcos I Restrepo; John R Downs; Antonio Anzueto Journal: JAMA Date: 2014-06-04 Impact factor: 56.272
Authors: L A Jackson; N L Smith; S R Heckbert; J T Grayston; D S Siscovick; B M Psaty Journal: Emerg Infect Dis Date: 1999 Mar-Apr Impact factor: 6.883
Authors: Yoriko Heianza; Wenjie Ma; Xiang Li; Yin Cao; Andrew T Chan; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi Journal: Circ Res Date: 2019-12-17 Impact factor: 17.367
Authors: Yoriko Heianza; Yan Zheng; Wenjie Ma; Eric B Rimm; Christine M Albert; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi Journal: Eur Heart J Date: 2019-12-14 Impact factor: 29.983
Authors: Malene Plejdrup Hansen; Anna M Scott; Amanda McCullough; Sarah Thorning; Jeffrey K Aronson; Elaine M Beller; Paul P Glasziou; Tammy C Hoffmann; Justin Clark; Chris B Del Mar Journal: Cochrane Database Syst Rev Date: 2019-01-18
Authors: Helen Blackshaw; Jane Vennik; Carl Philpott; Mike Thomas; Caroline Eyles; James Carpenter; Caroline S Clarke; Steve Morris; Anne Schilder; Valerie Lund; Paul Little; Stephen Durham; Spiros Denaxas; Elizabeth Williamson; David Beard; Jonathan Cook; Steffi Le Conte; Kim Airey; Jim Boardman; Claire Hopkins Journal: Trials Date: 2019-04-23 Impact factor: 2.279
Authors: Carl Philpott; Steffi le Conte; David Beard; Jonathan Cook; William Sones; Steve Morris; Caroline S Clarke; Mike Thomas; Paul Little; Jane Vennik; Valerie Lund; Helen Blackshaw; Anne Schilder; Stephen Durham; Spiros Denaxas; James Carpenter; James Boardman; Claire Hopkins Journal: Trials Date: 2019-04-29 Impact factor: 2.279